Skip to main content

Advertisement

Log in

Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics

  • Pharmacodynamics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objectives

This study aimed to establish a pharmacodynamic model to quantitatively compare the efficacy characteristics of seven kinds of triptans and their different dosage forms in the treatment of acute migraines.

Methods

Clinical studies of triptans in the treatment of acute migraines were comprehensively searched in the public databases. Pharmacodynamic models were established to describe the dose-effect and time-course of each kind of triptan for the proportion of patients who became pain free or had pain relief.

Results

A total of 92 articles involving 47,376 subjects were included in the analysis. After eliminating the placebo effect, oral eletriptan (40 mg) had the highest efficacy among all oral drugs at the maximum approved dose, and the proportion of patients who became pain free and had pain relief were 30.9% and 37.9% at 2 h, respectively. However, oral naratriptan (2.5 mg) had the lowest efficacy, and the proportion of patients who became pain free and had pain relief was 10.3% and 21.6% at 2 h, respectively. The efficacy of subcutaneous administration was significantly higher than that of oral administration, and the efficacy of nasal spray administration was comparable to that of oral administration. Regarding the dose-effect, the efficacy of the sumatriptan nasal spray significantly increased within the FDA (Food and Drug Administration)-approved dose range. When the dose was increased from 5 to 20 mg of sumatriptan nasal spray, the proportion of patients who became pain free and had pain relief increased by 16.8% and 18.3% at 2 h, respectively. Regarding the time-course, the time of onset of subcutaneous sumatriptan (6 mg) was the fastest, and the fraction of patients who were pain free at 2 h accounted for 90.6% of that at 4 h.

Conclusions

This study evaluated the efficacy characteristics of seven kinds of triptans and their different dosage forms. The present findings provide necessary quantitative information for migraine medication guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Schulman EA, Cady RK, Henry D, Batenhorst AS, Putnam DG, Watson CB, O'Quinn SO (2000) Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 75(8):782–789

    Article  CAS  PubMed  Google Scholar 

  2. Thorlund K, Mills EJ, Wu P, Ramos E, Chatterjee A, Druyts E, Goadsby PJ (2014) Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia 34(4):258–267

    Article  PubMed  Google Scholar 

  3. Dowson AJ, Massiou H, Laínez JM, Cabarrocas X (2002) Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia 22(6):453–461

    Article  CAS  PubMed  Google Scholar 

  4. Marmura MJ, Silberstein SD, Schwedt TJ (2015) The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache 55(1):3–20

    Article  PubMed  Google Scholar 

  5. Diener HC (1994) A review of current treatments for migraine. Eur Neurol 34(Suppl 2):18–25

    Article  PubMed  Google Scholar 

  6. Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ, Eletriptan and Cafergot Comparative Study Group (2002) Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 47(2):99–107

    Article  PubMed  Google Scholar 

  7. Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM, The 042 Clinical Trial Study Group (1997) Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology 49(5):1219–1225

    Article  CAS  PubMed  Google Scholar 

  8. Block GA, Goldstein J, Polis A, Reines SA, Smith ME (1998) Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups. Headache 38(10):764–771

    Article  CAS  PubMed  Google Scholar 

  9. Krymchantowski AV, Barbosa JS (2002) Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 22(4):309–312

    Article  CAS  PubMed  Google Scholar 

  10. Xu H, Han W, Wang J, Li M (2016) Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain 17(1):113

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mandema JW, Cox E, Alderman J (2005) Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain--results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia 25(9):715–725

    Article  CAS  PubMed  Google Scholar 

  12. Shuster JJ (2011) Review: Cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 3/2011. Julian P.T. Higgins and Sally Green, Editors [J]. Res Synth Methods 2(2):126–130

    Article  Google Scholar 

  13. Moskowitz MA, Cutrer FM (1993) SUMATRIPTAN: a receptor-targeted treatment for migraine. Annu Rev Med 44:145–154

    Article  CAS  PubMed  Google Scholar 

  14. Goadsby PJ, Hargreaves RJ (2000) Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan. Neurology 55(9 Suppl 2):S8–S14

    CAS  PubMed  Google Scholar 

  15. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB (2002) Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22(8):633–658

    Article  CAS  PubMed  Google Scholar 

  16. Ashcroft DM, Millson D (2004) Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf 13(2):73–82

    Article  CAS  PubMed  Google Scholar 

  17. Thorlund K, Toor K, Wu P, Chan K, Druyts E, Ramos E, Bhambri R, Donnet A, Stark R, Goadsby PJ (2017) Comparative tolerability of treatments for acute migraine: a network meta-analysis. Cephalalgia 37(10):965–978

    Article  PubMed  Google Scholar 

  18. Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, Peterson J, Coyle D, Skidmore B, Gomes T, Clifford T, Wells G (2015) Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache 55(Suppl 4):221–235

    Article  PubMed  Google Scholar 

  19. Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L (2005) Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs 19(2):125–136

    Article  CAS  PubMed  Google Scholar 

  20. Diamond S, Freitag FG, Feoktistov A, Nissan G (2007) Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who historically fail to respond to oral triptans. J Headache Pain 8(1):13–18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Ferrari MD (2002) Tripstar: a comprehensive patient-based approach to compare triptans. Headache 42(Suppl 1):18–25

    Article  PubMed  Google Scholar 

  22. Cady RK, McAllister PJ, Spierings ELH, Messina J, Carothers J, Djupesland PG, Mahmoud RA (2015) A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study). Headache 55(1):88–100

    Article  PubMed  Google Scholar 

  23. Diamond S, Elkind A, Jackson RT, Ryan R, DeBussey S, Asgharnejad M (1998) Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med 7(3):234–240

    Article  CAS  PubMed  Google Scholar 

  24. Antonaci F, Chimento P, Diener HC, Sances G, Bono G (2007) Lessons from placebo effects in migraine treatment. J Headache Pain 8(1):63–66

    Article  PubMed  PubMed Central  Google Scholar 

  25. Dahlof C et al (2001) Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology 57(10):1811–1817

    Article  CAS  PubMed  Google Scholar 

  26. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A (2016) Recent advances in migraine therapy. Springerplus 5:637

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Akpunonu BE, Mutgi AB, Federman DJ, Volinsky FG, Brickman K, Davis RL, Gilbert § C, Asgharnejad M (1995) Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med 25(4):464–469

    Article  CAS  PubMed  Google Scholar 

  28. Maas HJ, Danhof M, Pasqua OED (2009) Analysis of the relationship between age and treatment response in migraine. Cephalalgia 29(7):772–780

    Article  CAS  PubMed  Google Scholar 

  29. Franconi F, Finocchi C, Allais G, Omboni S, Tullo V, Campesi I, Reggiardo G, Benedetto C, Bussone G (2014) Gender and triptan efficacy: a pooled analysis of three double-blind, randomized, crossover, multicenter, Italian studies comparing frovatriptan vs. other triptans. Neurol Sci 35(1 Supplement):99–105

    Article  PubMed  PubMed Central  Google Scholar 

  30. Ferrari MD, Loder E, McCarroll K, Lines CR (2001) Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia 21(2):129–136

    Article  CAS  PubMed  Google Scholar 

  31. Menshawy A, Ahmed H, Ismail A, Abushouk AI, Ghanem E, Pallanti R, Negida A (2018) Intranasal sumatriptan for acute migraine attacks: a systematic review and meta-analysis. Neurol Sci 39(1):31–44

    Article  PubMed  Google Scholar 

  32. Tfelt-Hansen P, Pascual J, Ramadan N, Dahlöf C, D'Amico D, Diener HC, Hansen JM, Lanteri-Minet M, Loder E, McCrory D, Plancade S, Schwedt T, International Headache Society Clinical Trials Subcommittee (2012) Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 32(1):6–38

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was provided by the Drug Innovation Major Project (2018ZX09711001-009, 2018ZX09734005-001-002, 2018ZX09734005-006, 2018ZX09731016, 2017ZX09304003), the project of Shanghai Municipal Health Planning Commission (2018YQ48), and Science and Technology Innovation Action Plan of Shanghai (17401970900).

Funding

This study was provided by the Drug Innovation Major Project (2018ZX09711001-009, 2018ZX09734005-001-002, 2018ZX09734005-006, 2018ZX09731016, 2017ZX09304003), the project of Shanghai Municipal Health Planning Commission (2018YQ48), and Science and Technology Innovation Action Plan of Shanghai (17401970900).

Author information

Authors and Affiliations

Authors

Contributions

Mengyuan Hou and Hongxia Liu contributed equally to this work; all the information was independently extracted by two researchers. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Qingshan Zheng or Lujin Li.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 732 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hou, M., Liu, H., Li, Y. et al. Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics. Eur J Clin Pharmacol 75, 1369–1378 (2019). https://doi.org/10.1007/s00228-019-02748-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-019-02748-4

Keywords

Navigation